Precigen, Inc.
PGENHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePrecigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune. Valued at $2.21B, PGEN is a mid-cap name in its sector. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Market Cap
$2.21B
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-28.14
EPS (TTM)
$-1.01
EPS (Fwd)
$-0.22
ROE
-837.1%
ROA
-18.1%
Cash
$38.2M
Total Debt
$98.3M
Free CF
-$100.1M
52W Change
43.0%
Annual Financials
Cash vs Debt
Where PGEN stands vs its 150-day and 200-day moving averages
As of the October 9, 2026 close, PGEN finished 43.13% above its 150-day moving average ($5.31) and 49.90% above its 200-day moving average ($5.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PGEN overbought or oversold?
At the October 9, 2026 close, PGEN's RSI(14) was 47.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $38.2M in cash, though total debt stands at $98.3M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$100.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -837.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $26.9M (2022) to $9.7M (2025), a 64% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.